Patents by Inventor Alan D. D'Andrea

Alan D. D'Andrea has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7459287
    Abstract: The present invention discloses methods for detecting exposure of a living subject to genotoxic agents, testing sensitivity to a genotoxic agent, and determining DNA damage caused by exposure to an agent, comprising detecting the presence of FANCD2-containing foci from a sample collected from said subject. The presence of concentrated foci is indicative of DNA damage, and the degree of foci formation is correlated with degree of exposure. Diagnostic reagents contain a ligand that binds to human FANCD2 associated with a detectable label. Kits for detecting DNA damage in a biological sample contain such diagnostic reagents and signal detection components. The invention further discloses methods for identifying agents which modulate the ability of FANCD2-containing foci to form. Among other things, such agents are potentially useful chemosensitizing agents or may confer protection against damage caused by genotoxic agents.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: December 2, 2008
    Assignee: Dana Farber Cancer Institute, Inc.
    Inventor: Alan D. D'Andrea
  • Publication number: 20030188326
    Abstract: Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway.
    Type: Application
    Filed: June 6, 2002
    Publication date: October 2, 2003
    Applicant: Dana Farber Cancer Institute
    Inventors: Alan D. D'Andrea, Toshiyasu Taniguchi, Cynthia Timmers, Markus Grompe, Edward A. Fox
  • Publication number: 20030093819
    Abstract: Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, mapped on the 3p chromosome, cloned into recombinant vectors, used to prepare recombinant cells and sequenced. The FANCD2 gene sequence provides probes and primers for screening patients in genetic based tests and for diagnosing Fanconi anemia and cancer. It has also been possible to target the FANCD2 gene in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. Vectors are described for use in gene therapy. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the mono-ubiquinated FANCD-L form.
    Type: Application
    Filed: November 2, 2001
    Publication date: May 15, 2003
    Inventors: Alan D. D'Andrea, Toshiyasu Taniguchi, Cynthia Timmers, Markus Grompe
  • Patent number: 6287858
    Abstract: The present invention relates to ubiquitin-specific thiol proteases or deubiquitinating enzymes, referred to as DUB (DeUBiquitinating) enzymes, of eukaryotic origin which are members of a superfamily of deubiquitinating enzymes and which comprise a new subfamily of deubiquitinating enzymes which are similar in size and amino acid sequence to one another. DUB enzymes of the present invention are of eukaryotic origin, such as vertebrate origin, including mammalian (e.g., murine, human) origin, as well as yeast origin. All DUB enzymes of the present invention are inducible by at least one cytokine.
    Type: Grant
    Filed: February 5, 1998
    Date of Patent: September 11, 2001
    Assignee: Dana Farber Cancer Institute
    Inventors: Alan D. D'Andrea, Yuan Zhu